logo

For the Inventor, By the Inventor

Ichikawa, Japan

Taka-aki Okita

This inventor holds 6 USPTO granted patents. Top assignee: Bristol-Myers Company. Active years: 1979-1981.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Taka-aki Okita. Retrieved from https://idiyas.com/inventor/taka-aki-okita

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 6

% Patents Active = 100.0

Average Co-Inventor Count = 5.0

ph-index = 4

Forward Citations = 61(Granted Patents)


Company Filing History:

goldMedal6 out of 637 
 
Bristol-Myers Company
 patents

Years Active: 1979-1981

Loading Chart...
6 patents (USPTO):Explore Patents
1. 4278675 - Bronchodilating process (1981-07-14),
2. 4269839 - Alkylthio-adenines used as bronchodilators (1981-05-26),
3. 4241063 - Purine derivatives and their use as bronchodilators (1980-12-23),
4. 4232155 - Purine compounds (1980-11-04),
5. 4201860 - Purine derivatives (1980-05-06),
6. 4172829 - 2,9-Disubstituted adenine derivatives and their use as non-adrenergic (1979-10-30),

Title: Taka-aki Okita: Innovator in Bronchodilating Processes

Introduction

Taka-aki Okita is a notable inventor based in Ichikawa, Japan. He has made significant contributions to the field of bronchodilators, holding a total of 6 patents. His work focuses on innovative processes that enhance respiratory treatments.

Latest Patents

Among his latest patents, Okita has developed a bronchodilating process that employs purine derivatives, specifically '9-cyclohexyl-9H-adenine' and '9-benzyl-2-n-propoxy-9H-adenine'. This process aims to improve the efficacy of bronchodilation. Additionally, he has patented alkylthio-adenines that are used as bronchodilators. These adenine derivatives feature 2-alkylthio and 9-(2-cyclohexenyl or cyclohexyl) substituents, which exhibit non-adrenergic bronchodilating properties. They are intended for the treatment or prophylaxis of bronchoconstriction in mammals.

Career Highlights

Taka-aki Okita is associated with Bristol-Myers Company, where he continues to innovate in the field of respiratory therapies. His work has been instrumental in advancing bronchodilator treatments, contributing to better health outcomes for patients with respiratory conditions.

Collaborations

Okita has collaborated with notable colleagues, including Takayuki Naito and Susumu Nakagawa. Their combined expertise has fostered advancements in the development of bronchodilating agents.

Conclusion

Taka-aki Okita's contributions to bronchodilating processes highlight his role as a key innovator in respiratory medicine. His patents reflect a commitment to improving therapeutic options for patients, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…